We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cabozantinib plus Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer.
- Authors
Kuznar, Wayne
- Abstract
In this article the author talks about Combining cabozantinib with atezolizumab induced responses in patients with metastatic castration-resistant prostate cancer who had soft-tissue progression after previous novel hormonal therapy. Topics discussed Cabozantinib promotes an immune-permissive environment that may enhance response to immune checkpoint inhibitors, and the views of Neeraj Agarwal, Director, of Genitourinary Oncology Program at University of Utah, Salt Lake City.
- Subjects
PROSTATE cancer; IMMUNE checkpoint inhibitors
- Publication
Oncology Practice Management, 2020, Vol 10, Issue 4, p1
- ISSN
2164-4403
- Publication type
Article